Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Boehringer Ingelheim
McKinsey
AstraZeneca
McKesson

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021660

See Plans and Pricing

« Back to Dashboard

NDA 021660 describes ABRAXANE, which is a drug marketed by Abraxis Bioscience and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ABRAXANE profile page.

The generic ingredient in ABRAXANE is paclitaxel. There are sixty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.
Summary for 021660
Tradename:ABRAXANE
Applicant:Abraxis Bioscience
Ingredient:paclitaxel
Patents:12
Formulation / Manufacturing:see details
Pharmacology for NDA: 021660
Physiological EffectMicrotubule Inhibition
Medical Subject Heading (MeSH) Categories for 021660
Suppliers and Packaging for NDA: 021660
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660 NDA Abraxis BioScience, LLC 68817-134 68817-134-50 1 VIAL, SINGLE-USE in 1 CARTON (68817-134-50) > 20 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;IV (INFUSION)Strength100MG/VIAL
Approval Date:Jan 7, 2005TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 6, 2020
Regulatory Exclusivity Use:TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
Patent:  Start TrialPatent Expiration:Feb 21, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF PANCREATIC CANCER
Patent:  Start TrialPatent Expiration:Oct 27, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF BREAST CANCER

Expired US Patents for NDA 021660

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005   Start Trial   Start Trial
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005   Start Trial   Start Trial
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
McKinsey
Merck
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.